Acute Myeloid Leukemia Excellence Forum

Acute Myeloid Leukemia

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Interview

Dr Pettit Highlights Whether Low-Risk MDS Is Really Low Risk

10/20/2021

Kristen Pettit, MD, discusses MDS and highlights if low-risk MDS is really low risk. These data were presented at the virtual 2021 LL&M Congress.

Kristen Pettit, MD, discusses...

10/20/2021

Oncology

Interview

Dr Walker Discusses Chemo Plus Oblimersen in Patients With AML

10/01/2021

Alison R. Walker, MD, discusses the background, findings, and clinical significance of a phase 3 trial on chemotherapy with or without oblimersen in older patients with AML.

Alison R. Walker, MD, discusses...

10/01/2021

Oncology

Videos

Dr Abdelhakim Discusses NGS To Detect MRD Before HSCT in AML

08/31/2021

Haitham Abdelhakim, MD, discusses a meta-analysis on using NGS to detect MRD in patients with AML undergoing HSCT; the data of which were presented at the virtual 2021 ASCO Annual Meeting.

Haitham Abdelhakim, MD,...

08/31/2021

Oncology

Laura Agresta, MD, of Michigan State University

Videos

Dr Agresta Talks Venetoclax, CPX-351 for Young Patients With R/R AML

08/20/2021

Laura Agresta, MD, discusses a study on venetoclax and CPX-351 in young patients with relapsed/refractory AML; these data were presented at the virtual 2021 ASCO Annual Meeting.

Laura Agresta, MD, discusses a...

08/20/2021

Oncology

Videos

Ilaria Michelozzi, PhD, Discusses CAR T-Cell Targeting in AML

07/26/2021

Dr Michelozzi discusses therapeutic targeting using CAR T-cells in patients with AML.

Dr Michelozzi discusses...

07/26/2021

Oncology

Conference Insider

Harry Erba, Md, PhD, Discusses Treatment Shift in AML with Maintenance Therapy

07/16/2021

Harry Erba, MD, PhD, discusses how the treatment paradigm for AML has changed with maintenance therapy.

Harry Erba, MD, PhD, discusses...

07/16/2021

Oncology

Videos

Mark Levis, MD, PhD, Discusses FLT3 Inhibition in Relapsed/Refractory AML

06/05/2021

Dr Levis discusses a study examining FF-10101-01, an irreversible FLT3 inhibitor, in patients with relapsed/refractory AML, which was presented at the 2021 ASCO Annual Meeting.

Dr Levis discusses a study...

06/05/2021

Oncology

Richard Stone, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts

Interview

Richard Stone, MD, on Updates in the Treatment of High-Risk AML

05/19/2021

Richard M. Stone, MD, recently shared updates on the treatment of high-risk AML at the Second Summit of the Americas on Immunotherapies for Hematologic Malignancies.

Richard M. Stone, MD, recently...

05/19/2021

Oncology

Interview

Molly Schroeder, PhD, on WGS as an Alternative to Cytogenetics in AML, MDS

04/22/2021

Dr Schroeder spoke on the findings and significance of a study on whole genome sequencing as an alternative to cytogenetic analysis in myeloid cancers.

Dr Schroeder spoke on the...

04/22/2021

Oncology

Videos

Dr Koehne Talks Hot Topics in Hematology at the Miami Cancer Institute Summit

03/22/2021

Guenther Koehne, MD, discusses highlights from the Second Summit of the Americas on Immunotherapy for Hematologic Malignancies.

Guenther Koehne, MD, discusses...

03/22/2021

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology